[1]韩庭良△ 王国军 尹佩玉 阳启进.PKP联合补肾活血方治疗骨质疏松椎体压缩骨折的临床研究[J].中国中医骨伤科杂志,2016,24(10):35-39.
　HAN Tingliang WANG Guojun YIN Peiyu YANG Qijing.Effect of Percutaneous Kyphoplasty Combined with Bushen HuoxueDecoction for Treating Osteoporotic Vertebral Compression Fractures[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2016,24(10):35-39.
点击复制

PKP联合补肾活血方治疗骨质疏松椎体压缩骨折的临床研究
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第24卷
期数:
2016年10期
页码:
35-39
栏目:
临床研究
出版日期:
2016-10-01

文章信息/Info

Title:
Effect of Percutaneous Kyphoplasty Combined with Bushen Huoxue Decoction for Treating Osteoporotic Vertebral Compression Fractures
文章编号:
1005-0205(2016)10-0035-05
作者:
韩庭良1△ 王国军1 尹佩玉1 阳启进1
1.江苏盐城市中医院骨伤二科(江苏 盐城,224002)
△.通信作者 E-mail:Drxyz120@sina.com
Author(s):
HAN Tingliang1△ WANG Guojun1 YIN Peiyu1 YANG Qijing1
1.Department of Orthopedics, Yancheng Hospital of Traditional Chinese Medicine, Yancheng 2224002,Jiangsu China.
关键词:
骨质疏松症;  椎体压缩骨折;  经皮后凸成形术;  补肾活血汤
Keywords:
osteoporosis;  vertebral compression fracture;  percutaneous kyphoplasty;  Bushen Huoxue decoction
分类号:
R683.2
文献标志码:
A
摘要:
目的:研究补肾活血中药联合经皮椎体成形术治疗骨质疏松椎体压缩骨折的疗效优势。方法:纳入2013年6月至2015年6月接受椎体成形术治疗的骨质疏松椎体压缩骨折(OVCF)患者,影像及随访资料完整者54例。联合补肾活血方+PKP组共33例、39节椎体,单纯PKP组共21例、25节椎体。记录患者一般资料(年龄、性别、病程、骨密度、骨折节段分布等),手术相关信息(手术时间、骨水泥注入量等)。分别于术前、术后1周内、术后1～6个月随访视觉模拟疼痛VAS评分、功能障碍ODI评分和SF-36生活质量评分,分别作组间比较。结果:两组患者的年龄、性别构成比、骨密度、伤椎分布等均无差异。术前和术后1周内随访的VAS评分、ODI评分差异无统计学意义。术后14 d及1个月、6个月随访的PKP+补肾活血中药组VAS,ODI,SF-36中四维度(PF,BP,VT,SF)评分较PKP组更好,差异有统计学意义。术后1个月和6个月随访中,PKP+补肾活血中药组在SF-36的另外两个维度(RP、GH)也显示出优势。结论:联合应用补肾活血中药有助于增强和保持椎体成形术治疗骨质疏松椎体压缩骨折的疗效,值得临床关注。
Abstract:
Objective:To compare the curative effect between percutaneous kyphoplasty(PKP)and PKP combined with Bushen Huoxue decoction for osteoporotic vertebral compression fractures(OVCFs). Methods:We retrospectively selected 54 patients who underwent PKP for OVCFs between June 2013 to June 2015 with detailed follow-up information(39 vertebral of 33 cases underwent PKP combined with Bushen Huoxue decoction and 25 vertebral of 21 cases underwent PKP). General clinical data, such as sex, age, clinical course, bone density, different segments of the fractures, etc, and surgical data, such as operation time, cement volume of all patients were recorded. The VAS score, ODI score, and SF-36 quality of life score were recorded and compared at 1 week before surgery and 1 week, 1 to 6 months after surgery. Results:There was no significant difference in general data, such as age, sex, bone mineral density, and different segments of the fractures, between the two groups. There was no significant difference in the VAS score, ODI score, and SF-36 quality of life score between the two groups 1 week before and after surgery. The score of VAS, ODI and SF-36(PF, BP, VT and SF)in the patients underwent PKP combined with Bushen Huoxue decoction were significantly better than the patients underwent PKP only at the 14th days, 1st month, and 6th months after surgery. And the score of SF-36(RP and GH)in the patients underwent PKP combined with Bushen Huoxue decoction were also significantly better than the patients underwent PKP at the 1st and 6th months after surgery. Conclusion: The PKP combined with Bushen Huoxue decoction is more effective for treating OVCFs compared with PKP only.

参考文献/References:

[1] Curtis EM,Moon RJ,Dennison EM,et al.Recent advances in the pathogenesis and treatment of osteoporosis[J].Clin Med(Lond),2015,15(6):92-96.
[2] Kendler DL,Bauer DC,Davison KS,et al.Vertebral fractures:clinical importance and management[J].Am J Med,2016,129(2):221.e1-221.e10.
[3] Goldstein CL,Chutkan NB,Choma TJ,et al.Management of the elderly with vertebral compression fractures[J].Neurosurgery,2015,77(4):33-45.
[4] Takahara K,Kamimura M,Moriya H,et al.Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women[J].BMC Musculoskelet Disord,2016,17(1):12.
[5] Staples MP,Howe BM,Ringler MD,et al.New vertebral fractures after vertebroplasty:2-year results from a randomised controlled trial[J].Arch Osteoporos,2015,10:229.
[6] Santos RF,Ribeiro JC,de Moraes FB,et al.Evaluation of the quality of life after vertebroplasty to treat compressive osteoporotic fractures[J].Rev Bras Ortop,2014,49(5):477-481.
[7] Schousboe JT.Epidemiology of vertebral fractures[J].J Clin Densitom,2016,19(1):8-22.
[8] Liliang PC,Lu K,Shen SH.Persistent back pain after percutaneous vertebroplasty[J].Pain Med,2015,16(3):554-555.
[9] In erratum:Residual Back Pain after Vertebroplasty[J].Pain Physician,2015,18(1):107.
[10] Yan Y,Xu R,Zou T.Is thoracolumbar fascia injury the cause of residual back pain after percutaneous vertebroplasty? A prospective cohort study[J].Osteoporos Int,2015,26(3):1119-1124.
[11] 蒋卫方.椎体成形术配合补肾活血中药治疗骨质疏松性胸腰椎骨折51例临床观察[J].江苏中医药,2013,45(12):38-39.
[12] 张华龙.手术联合补肾活血中药治疗骨质疏松性胸腰椎压缩性骨折20例[J].中医药导报,2010,16(4):49-50.
[13] 袁瑞萍.中药辨证施治在骨质疏松症治疗中的研究进展[J].慢性病学杂志,2013,14(12):922-923.
[14] 赵晓玲,彭勇.中药防治骨质疏松症的研究进展[J].中国现代中药,2012,14(8):16-20.
[15] 年华,徐玲玲,马明华,等.抗骨质疏松中药的研究现状[J].上海中医药大学学报,2008,22(4):90-93.
[16] 张方珍,宋长恒,付小卫,等.骨质疏松症的中医治则治法探讨[J].中国中医基础医学杂志,2014,20(9):1192-1194.
[17] 王雪娇,吴琼,李咏梅.辨证论治骨质疏松症[J].吉林中医药,2012,32(6):576-577.
[18] 许兵,金红婷,刘慧,等.补肾活血颗粒对去势大鼠骨组织Wnt/β-Catenin通路的影响研究[J].中华中医药杂志,2013,20(11):3400-3405.
[19] 黎晓敏,卢昌均,周艳芳,等.黄芪三仙汤干预成骨细胞护骨素及护骨素配体的表达[J].中国组织工程研究,2013,17(11):1939-1945.
[20] 许兵,方剑利,刘慧,等.补肾活血方对去势大鼠骨质疏松的影响[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(3):177-182.
[21] 朱晓峰,王廷春,杨丽,等.补肾活血中药复方对去卵巢大鼠骨密度和骨组织神经肽Y的影响[J].中国老年学杂志,2015,35(11):2884-2886.
[22] 孙鑫,杨芳,邓洋洋,等.补肾、健脾、活血法对骨质疏松症小鼠骨及骨骼肌中Na～+-K～+-ATP酶含量的影响[J].中华中医药杂志,2014,29(12):3787-3789.

更新日期/Last Update: 2016-10-15